Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

Lung Cancer Incidence in the Arab League Countries: Risk Factors and Control

Salim, Elsayed I;Jazieh, Abdul Rahman;Moore, Malcolm A

  • Published : 20110100
⟨ Previous Next ⟩

Abstract

Although lung cancer incidence rates and mortalities are still low in the Arab world as compared to Europe or USA, they is gradually increasing in the region. Furthermore, there is great variation between different parts of the Arab world. For instance, the age-standardized rates (ASRs) for lung cancer incidence are about 15 fold higher in Tunisia than in Sudan for men, and about 10 fold higher in Bahrain than in Yemen for females. Percentage data for both sexes of lung cancer in the Arab world show that 15/22 (68.1%) of the Arab countries have lung cancer as one of the most frequent five types of cancer. Despite major advances in understanding and treating cancer, the 5-year relative survival rate in North Africa and the Middle East is only 8%. With the notable exception of Algeria, and to a lesser extent Tunisia, where squamous cell carcinomas are more common, the two main types show approximately the same proportions in males, while adenocarcinomas tend to predominate in females. The estimated numbers of new lung cancer cases in 2008 were 9,537 in ages below 65 for both sexes, and 7,059 cases for ages above 65. In 2020 there is expected to be 14,788 new lung cancer cases in the Arab countries for ages below 65, and 14,788 cases for ages above 65 in both males and females. Between 1990 and 1997, cigarette consumption increased 24% in the Middle East, one of only two regions of the world where cigarette sales increased during that period, so that continued rise in cancer rates can be expected. Improvement of tobacco control, registration and treatment are all necessary to decrease the burden of lung cancer in the Arab world.

Keywords

References

  1. Abu Idris DO, Ahmed AO, Elmadani AE, et al (2009). Cancer management in Sudan: current status and future perspectives. Sudan J Med Sci, 4, 189-93.
  2. Albright C, Garst J (2007). Vaccine therapy in non-small cell lung cancer. Current Oncology Reports, 9, 241-6. https://doi.org/10.1007/s11912-007-0029-9
  3. Al-Hamdan N, Al-Jarallah M, Al-Jarallah M, et al (2006). The incidence of lung cancer in the Gulf Cooperation Council countries. Ann Saudi Med, 26, 433-8. https://doi.org/10.5144/0256-4947.2006.433
  4. Al Hasnawi S, Al khuzaie A, Al Mosawi AJ, et al (2009). The Histopathological pattern of lung cancer in Iraq. N Iraqi J Med, 5, S80-3.
  5. Al-Kawari M, Alsayyad J, Bazarbashi S, et al (2009). Eight-Year Cancer Incidence Among Nationals of the GCC States 1998-2005), 1-151 (www.sgh.org.sa).
  6. Association Lalla Salma de Lutte Contre le Cancer. Registre des Cancers de la region du grand Casablanca (Annee 2004), Edition 2007 at: http://www.emro.who.int/ncd/pdf/cancer_registry_mor.pdf.
  7. Aviel-Ronen S, Blackhall FH, Shepherd FA, et al (2006). K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer, 8, 30-8. https://doi.org/10.3816/CLC.2006.n.030
  8. Bahader Y, Jazieh A-H (2008). Epidemiology of lung cancer. Annals of Thoracic medicine, Supplement: Lung Cancer Guidelines, s65-7 (http://www.thoracicmedicine.org).
  9. Bani-Hani KE, Gharaibeh KA (2005). Malignant peritoneal mesothelioma. J Surg Oncol, 91, 17-25. https://doi.org/10.1002/jso.20266
  10. Ba Saleem HO, Bawazir AA, Moore M, et al (2010). Five years cancer incidence in aden cancer registry, Yemen (2002-2006). Asian Pac J Cancer Prev, 11, 507-11.
  11. Bastide K, Guilly MN, Bernaudin JF, et al (2009). Molecular analysis of the Ink4a/Rb1-Arf/Tp53 pathways in radoninduced rat lung tumors. Lung Cancer, 63, 348-53. https://doi.org/10.1016/j.lungcan.2008.06.007
  12. Bawazir AA (2006). Tobacco Related Cancer Incidence in Republic of Yemen 2003, The 13th World Conference on Tobacco OR Health Building capacity for a tobacco-free world July 12-5, 2006, Washington, DC, USA).
  13. B'chir F, Laouani A, Ksibi S, et al (2007). Cigarette filter and the incidence of lung adenocarcinoma among Tunisian population. Lung Cancer, 57, 26-33. https://doi.org/10.1016/j.lungcan.2007.01.034
  14. Bencardino K, Manzoni M, Delfanti S, et al (2007). Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. Intern Emerg Med, 2, 3-12. https://doi.org/10.1007/s11739-007-0002-5
  15. Benghazi Cancer Registry. Cancer Incidence and Mortality in Eastern Libya, 2004. (http://www.cancerlibya.com)
  16. Berthiller J, Straif K, Boniol M, et al (2008). Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Onco, 3, 1398-403. https://doi.org/10.1097/JTO.0b013e31818ddcde
  17. Biesalski HK, Bueno de Mesquita B, Chesson A, et al (1998). European consensus statement on lung cancer: risk factors and prevention. Lung cancer panel. CA Cancer J Clin (Smoking is the major risk factor, accounting for about 90% of lung cancer incidence), 48, 167-76. https://doi.org/10.3322/canjclin.48.3.167
  18. Blackhall FH, Shepherd FA (2007). Small cell lung cancer and targeted therapies. Current Opinion Oncol, 19, 103-8. https://doi.org/10.1097/CCO.0b013e328011bec3
  19. Blons H, Pallier K, Le Corre D, et al (2008). Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC Med Genomics, 12, 1-25.
  20. Bray F, Tyczynski JE, Parkin DM (2004). Going up or coming down? The changing phases of the lung cancer epidemic in the 15 European Union countries 1967-1999. Eur J Cancer, 40, 96-125. https://doi.org/10.1016/j.ejca.2003.08.005
  21. Bryant A, Cerfolio RJ (2007). Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest, 132, 185-92. https://doi.org/10.1378/chest.07-0442
  22. Byers T (2008). Nutrition and lung cancer: lessons from the differing effects of foods and supplements. Am J Respir Crit Care Med, 177, 470-1. https://doi.org/10.1164/rccm.200711-1681ED
  23. Cancer incidence in Oman 2008, MOH, Sultanate of Oman; (www.moh.gov.om).
  24. Catelinois O, Rogel A, Laurier D, et al (2006). Lung cancer attributable to indoor radon exposure in france: impact of the risk models and uncertainty analysis. Environ Hlth Perspect, 114, 1361-6. https://doi.org/10.1289/ehp.9070
  25. CBCF: Congressional Black Caucus Foundation, 2004 (http://www.cbcfinc.org/newsroom/annual-reports.html).
  26. Chiang YJ, Calado RT, Hathcock KS, et al (2010). Telomere length is inherited with resetting of the telomere set-point. Proc Natl Acad Sci USA, 107, 10148-53. https://doi.org/10.1073/pnas.0913125107
  27. Chlebowski RT, et al (2009). Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the women's health initiative randomized clinical trial. J Clin Oncol, 27, CRA1500. https://doi.org/10.1200/jco.2009.27.18_suppl.cra1500
  28. Chopra SA, Chopra FS (1977). Cancer in the Africans and Arabs of Zanzibar. Int J Cancer, 19, 298-304. https://doi.org/10.1002/ijc.2910190304
  29. Chung A (1994). Lung cancer cell type and occupational exposure. In: J.M. Samet, Editor, Epidemiology of lung cancer, Marcel Dekker Inc, New York; 413-36.
  30. Collins LG, Haines C, Perkel R, et al (2007). Lung cancer: diagnosis and management. Am Fam Physician, 75, 56-63.
  31. Curado MP, Edwards B, Shin HR, et al (eds) (2007). Cancer Incidence in Five Continents, Vol.IX, IARC Scientific Publications No. 160, Lyon IARC.
  32. Darby S, Hill D, Auvinen A, et al (2005). Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ, 330, 223. https://doi.org/10.1136/bmj.38308.477650.63
  33. Darnton AJ, McElvenny DM, Hodgson JT (2006). Estimating the number of asbestos-related lung cancer deaths in Great Britain from 1980 to 2000. Ann Occup Hyg, 50, 29-38.
  34. Darwish-Yassine M, Wing D (2005). Cancer epidemiology in Arab Americans and Arabs outside the Middle East. Ethn Dis, 15, S1-5-8.
  35. Dempke WC, Suto T, Reck M (2010). Targeted therapies for non-small cell lung cancer. Lung Cancer, 67, 257-74. https://doi.org/10.1016/j.lungcan.2009.10.012
  36. Devereux TR, Taylor JA, Barrett JC (1996). Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Chest, 109, S14-9. https://doi.org/10.1378/chest.109.3_Supplement.14S
  37. Doll R, Peto R, Boreham J, et al (2005). Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer, 92, 426-9. https://doi.org/10.1038/sj.bjc.6602359
  38. Dosemeci M, Gokmen I, Unsal M, et al (1997). Tobacco, alcohol use, and risks of laryngeal and lung cancer by subsite and histologic type in Turkey. Cancer Causes Control, 8, 729-37. https://doi.org/10.1023/A:1018479304728
  39. Du L, Schageman JJ, Girard LI, et al (2010). MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J Exp Clin Cancer Res, 29, 75. https://doi.org/10.1186/1756-9966-29-75
  40. El Mistiri M, Verdecchia A, Rashid I, et al (2007). Cancer incidence in eastern Libya: the first report from the Benghazi cancer registry, 2003. Int J Cancer, 120, 392-7. https://doi.org/10.1002/ijc.22273
  41. Engels EA, Wu X, Gu J, et al (2007). Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res, 67, 6520-7. https://doi.org/10.1158/0008-5472.CAN-07-0370
  42. EPA (2006). Radiation information: radon. EPA. http://www.epa.gov/rpdweb00/radionuclides/radon.html.
  43. Etienne-Mastroianni B, Falchero L, Chalabreysse L, et al (2002). Primary sarcomas of the lung: a clinicopathologic study of 12 cases. Lung Cancer, 38, 283-9. https://doi.org/10.1016/S0169-5002(02)00303-3
  44. Feld R, Sridhar SS, Shepherd FA, et al (2006). Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol, 1, 367-76. https://doi.org/10.1097/01243894-200605000-00018
  45. Ferlay J, Shin HR, Bray F, et al (2010). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr
  46. Fontham ET, Correa P, Reynolds P, et al (1994). Environmental tobacco smoke and lung cancer in nonsmoking women: a multicenter study. J Am Med Assoc, 271, 1752-9. https://doi.org/10.1001/jama.1994.03510460044031
  47. Freedman LS, Edwards BK, Ries LAG, et al (2007). Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the middle east cancer consortium (MECC) compared with US SEER. In: lung cancer: Samir Al Kayed, M. Bassam Kassem. National cancer institute. NIH Pub. No. 06-5873. Bethesda, MD.
  48. Fujimoto J, Kadara H, Men T, et al (2010). Comparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5aknockout mice. PLoS One, 5, e11847. https://doi.org/10.1371/journal.pone.0011847
  49. Gaafar RM (2007). Asbestos and mesothelioma in Egypt: P1-118. J Thorac Oncol, 2, 597.
  50. Gervasini G, San Jose C, Carrillo JA, et al (2010). GST polymorphisms interact with dietary factors to modulate lung cancer risk: study in a high-incidence area. Nutr Cancer, 62, 750-8. https://doi.org/10.1080/01635581003605946
  51. Giuliani L, Jaxmar T, Casadio C, et al (2007). Detection of oncogenic viruses (SV40, BKV, JCV, HCMV, HPV) and p53 codon 72 polymorphism in lung carcinoma. Lung Cancer, 57, 273-81. https://doi.org/10.1016/j.lungcan.2007.02.019
  52. Gorlova OY, Weng SF, Zhang Y, et al (2007). Aggregation of cancer among relatives of never-smoking lung cancer patients. Int J Cancer, 121, 111-8. https://doi.org/10.1002/ijc.22615
  53. Habib OS, Al-Ali JK, Al-Wiswasi MK, et al (2007). Cancer registration in Basrah 2005: preliminary results. Asian Pac J Cancer Prev, 8, 187-90.
  54. Harris TJ, McCormick F (2010). The molecular pathology of cancer. Nat Rev Clin Oncol, 7, 251-65. https://doi.org/10.1038/nrclinonc.2010.41
  55. Hashibe M, Morgenstern H, Cui Y, et al (2006). Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev, 15, 1829-34. https://doi.org/10.1158/1055-9965.EPI-06-0330
  56. Hecht S (2003). Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer, 3, 733-44. https://doi.org/10.1038/nrc1190
  57. Herbst RS, Heymach JV, Lippman SM (2008). Molecular origins of cancer: lung cancer. N Engl J Med, 359, 1367-80. https://doi.org/10.1056/NEJMra0802714
  58. Hosny G, Akel M (2006). Assessment of Asbestos in Drinking Water in Alexandria, Egypt. J Egyptian Public Hlth Assoc, 81, 181-95.
  59. Ibrahim WH, Rasul KI, Khinji A, et al (2010). Clinical and epidemiological characteristics of lung cancer cases in Qatar. East Mediterr Hlth J, 16, 166-70.
  60. Jazieh A-R, Bamefleh H, Demirkazik A, et al (2010). Modification and Implementation of NCCN $Guidelines^{TM}$ on non-small cell lung cancer in the middle East and North Africa region. J National Comprehensive Cancer Network (NCCN), 8, S16-21. https://doi.org/10.6004/jnccn.2010.0118
  61. Jayachandran G, Sazaki J, Nishizaki M, et al (2007). Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. Cancer Res, 67, 10379-88. https://doi.org/10.1158/0008-5472.CAN-07-0677
  62. Jemal A, Chu KC, Tarone RE (2001). Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst, 93, 277-83. https://doi.org/10.1093/jnci/93.4.277
  63. Jemal A, Clegg LX, Ward E, et al (2004). Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer, 101, 3-27. https://doi.org/10.1002/cncr.20288
  64. Jenkins RA, Guerin MR, Tomkins BA (2000). The chemistry of environmental tobacco smoke: composition and measurement, CRC Press LLC, Boca Raton.
  65. Jiao S, Liu B, Gao A, et al (2008). Benzo(a)pyrene-caused increased G1-S transition requires the activation of c-Jun through p53-dependent PI-3K/Akt/ERK pathway in human embryo lung fibroblasts. Toxicol Lett, 178, 167-75. https://doi.org/10.1016/j.toxlet.2008.03.012
  66. Kabir Z, Bennett K, Clancy L (2007). Lung cancer and urban air-pollution in dublin: a temporal association? Irish Med J, 100, 367-9.
  67. Kattan J, Faraj H, Ghosn M, et al (2001). Mesothelioma-asbestos in Lebanon: a problem to be considered. J Med Liban, 49, 333-7.
  68. Krewski D, Burnett R, Jerrett M, et al (2009). Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res, 15, 5714-23. https://doi.org/10.1158/1078-0432.CCR-09-0070
  69. Kuper H, Boffetta P, Adami H-O (2002). Tobacco use and cancer causation: association by tumour type. J Intern Med, 252, 206-24. https://doi.org/10.1046/j.1365-2796.2002.01022.x
  70. Lee EB, Jin G, Lee SY, et al (2010). TP53 mutations in Korean patients with non-small cell lung cancer. J Korean Med Sci, 25, 698-705. https://doi.org/10.3346/jkms.2010.25.5.698
  71. Leroux C, Girard N, Cottin V, et al (2007). Jaagsiekte sheep retrovirus (JSRV): from virus to lung cancer in sheep. Vet Res, 38, 211-28. https://doi.org/10.1051/vetres:2006060
  72. Loboda A, Nebozhyn M, Klinghoffer R, et al (2010). A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics, 3, 26. https://doi.org/10.1186/1755-8794-3-26
  73. M'barek B, Kochbati L, Ben Mansour H, et al (2006). Occupational cancer in Tunisia. Tunis Med, 84, 30-3.
  74. Madkour MT, El Bokhary MS, Awad Allah HI, et al (2009). Environmental exposure to asbestos and the exposureresponse relationship with mesothelioma. East Mediterr Hlth J, 15, 25-38.
  75. Mackay J, Eriksen M (2002). The tobacco atlas. Geneva (Switzerland): World Health Organization.
  76. Mohr SB, Garland CF, Gorham ED, et al (2008). Could ultraviolet B irradiance and vitamin D be associated with lower incidence rates of lung cancer? J Epidemiol Community Hlth, 62, 69-74. https://doi.org/10.1136/jech.2006.052571
  77. Morandi U, Casali C, Rossi G (2006). Bronchial typical carcinoid tumors. Semin Thoracic Cardiovascular Surg, 18, 191-8. https://doi.org/10.1053/j.semtcvs.2006.08.005
  78. Murphy SE, Camella SG, Idris AM, et al (1994). Uptake and metabolism of carcinogenic levels of tobacco-specific nitrosamines by Sudanese Snuff Dippers. Cancer Epidemiol Biomarkers Prev, 3, 423-8.
  79. Nafstad P, Haheim LL, Wisloff T, et al (2004). Urban air pollution and mortality in a cohort Norwegian men. Environ Hlth Perspect, 112, 610-5. https://doi.org/10.1289/ehp.6684
  80. NCI (National Cancer Institute): Egypt. Cairo Registry, 2006. Available at: www.nci.edu.eg.
  81. Nordquist LT, Simon GR, Cantor A, et al (2004). Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest, 126, 347-51. https://doi.org/10.1378/chest.126.2.347
  82. O'Reilly KM, Mclaughlin AM, Beckett WS, et al (2007). Asbestos-related lung disease. Am Fam Physician, 75, 683-8.
  83. Pakkala S, Ramalingam SS (2010). Lung cancer in HIV-positive patients. J Thorac Oncol, 5, 1864-71. https://doi.org/10.1097/JTO.0b013e3181f387fd
  84. Parkin DM, Pisani P, Ferlay J (1999). Global Cancer Statistics 1999. CA Cancer J Clin, 49, 33-64. https://doi.org/10.3322/canjclin.49.1.33
  85. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, D74-108. https://doi.org/10.3322/canjclin.55.2.74
  86. Peto R, Lopez AD, Boreham J, et al (2006). Mortality from smoking in developed countries 1950-2000: Indirect estimates from National Vital Statistics. Oxford University Press. ISBN 0-19-262535-7. http://www.ctsu.ox.ac.uk/-tobacco/
  87. Raz DJ, He B, Rosell R, et al (2006). Bronchioloalveolar carcinoma: a review. Clin Lung Cancer, 7, 313-22. https://doi.org/10.3816/CLC.2006.n.012
  88. Sandler A, Gray R, Perry M, et al (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med, 355, 2542-50. https://doi.org/10.1056/NEJMoa061884
  89. Sasco AJ, Merrill RM, Dari I, et al (2002). A case-control study of lung cancer in Casablanca, Morocco. Cancer Causes Control, 13, 609-16. https://doi.org/10.1023/A:1019504210176
  90. Schick S, Glantz S (2005). Philip Morris toxicological experiments with fresh sidestream smoke: more toxic than mainstream smoke. Tobacco Control, 14, 396-404. https://doi.org/10.1136/tc.2005.011288
  91. Schmid K, Kuwert T, Drexler H (2010). Radon in indoor spaces: an underestimated risk factor for lung cancer in environmental medicine. Dtsch Arztebl Int, 107, 181-6.
  92. Saade G, Abou Jaoude S, Afifi R, et al (2008). Patterns of tobacco use: Results from the 2005 Global Youth Tobacco Survey in Lebanon. East Mediterr Hlth J, 14, 1280-9.
  93. Salim EI, Moore MA, Al-Lawati JA, et al (2009). Cancer epidemiology and control in the Arab world - past, present and future. Asian Pac J Cancer Prev, 10, 3-16.
  94. Samet JM, Wiggins CL, Humble CG, et al (1988). Cigarette smoking and lung cancer in New Mexico. Am Rev Respir Dis, 137, 1110-3. https://doi.org/10.1164/ajrccm/137.5.1110
  95. Shafey O (2007). Global Epidemiology and health hazards of tobacco use: Arab world patterns. Ethn Dis, 17, S3-13-15.
  96. Shamseddine AI, Musallam KM (2010). Cancer Epidemiology in Lebanon. Middle East J Cancer, 1, 41-4.
  97. Son JW, Kang HK, Chae MH, et al (2006). Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet, 169, 121-7. https://doi.org/10.1016/j.cancergencyto.2006.04.001
  98. Sopori M (2002). Effects of cigarette smoke on the immune system. Nature reviews. Immunology, 2, 372-7.
  99. Sorahan T (2009). Lung cancer mortality in arsenic-exposed workers from a cadmium recovery plant. Occup Med, 59, 264-6. https://doi.org/10.1093/occmed/kqp046
  100. Stein QP, Flanagan JD (2010). Genetic and familial factors influencing breast, colon, prostate and lung cancers. S D Med, Spec No:16-22.
  101. Stellman SD, Chen Y, Muscat JE, et al (2003). Lung cancer risk in white and black Americans. Ann Epidemiol, 13, 294-302. https://doi.org/10.1016/S1047-2797(02)00420-9
  102. Subramanian J, Govindan R (2007). Lung cancer in never smokers: a review. J Clin Oncol, 25, 561-70. https://doi.org/10.1200/JCO.2006.06.8015
  103. Sun S, Schiller JH, Spinola M, et al (2007). New molecularly targeted therapies for lung cancer. J Clin Investigation, 117, 2740-50. https://doi.org/10.1172/JCI31809
  104. The Egyptian Society of Chest diseases and Tuberculosis, (2006). Source:http://www.who.int/gard/news_events/1_tag_el_din_egypt.pdf
  105. Thun MJ, Lally CA, Flannery JT, et al (1997). Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst, 89, 1580-6. https://doi.org/10.1093/jnci/89.21.1580
  106. Thun MJ, SJ Henley, D Burns, et al (2006). Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst, 98, 691. https://doi.org/10.1093/jnci/djj187
  107. Thun MJ, Hannan LM, Adams-Campbell LL, et al (2008). Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med, 5, e185. https://doi.org/10.1371/journal.pmed.0050185
  108. Travis WD, Travis LB, Devesa SS (1995). Lung cancer. Cancer, 75, 191-202. https://doi.org/10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y
  109. Travis WD, Brambilla E, Muller-Hermelink HK, et al (2004): World health organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press: Lyon.
  110. Tyczynski JE, Bray F, Aareleid T, et al (2004). Lung cancer mortality patterns in selected Central, Eastern and Southern European countries. Int J Cancer, 109, 598-610. https://doi.org/10.1002/ijc.20019
  111. US Department of Health Education and Welfare (1964). Smoking and health: report of the advisory committee to the surgeon general of the public health service (PDF). Washington, DC: US government printing office. http://profiles.nlm.nih.gov/NN/B/B/M/Q/_/nnbbmq.pdf
  112. US Department of Health and Human Services (1990). The health benefits of smoking cessation: a report of the surgeon general. Centers for disease control (CDC), office on smoking and health. pp. vi, 130, 148, 152, 155, 164, 166. http://profiles.nlm.nih.gov/NN/B/B/C/T/_/nnbbct.pdf.
  113. Valavanidis A, Fiotakis K, Vlachogianni T (2008). Airborne particulate matter and human health: toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 26, 339-62. https://doi.org/10.1080/10590500802494538
  114. Vaporciyan AA Nesbitt JC, Lee JS, et al (2000). Cancer Med, 1227-92.
  115. Villeneuve PJ, Mao Y (1994). Lifetime probability of developing lung cancer, by smoking status, Canada. Canadian J Public Hlth, 85, 385-8.
  116. Wen W, Shu XO, Gao YT, et al (2006). Environmental tobacco smoke and mortality in Chinese women who have never smoked: prospective cohort study. BMY, 333, 376.
  117. Wenzlaff AS, Cote ML, Bock CH, et al (2005). CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis, 26, 2207-12. https://doi.org/10.1093/carcin/bgi191
  118. WHO (1997). Tobacco or health: a global status report. Geneva, Switzerland: world health organization.
  119. WHO report on the global tobacco epidemic, 2009- Appendix VII: "Age-standardized prevalence estimates for smoking, 2006, E307-37.
  120. World Cancer Congress and the 13th World Conference on Tobacco OR Health (2006), Washington, D.C.
  121. Wiencke JK, Thurson SW, Kelsey KT, et al (1999). Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. J Natl Cancer Inst, 91, 614-9. https://doi.org/10.1093/jnci/91.7.614
  122. Wright ME, Park Y, Subar AF, et al (2008). Intakes of fruit, vegetables, and specific botanical groups in relation to lung cancer risk in the NIH-AARP diet and health study. Am J Epidemiol, 168, 1024-34. https://doi.org/10.1093/aje/kwn212
  123. Yao R, Wang Y, D'Agostini F, et al (2005). K-ras mutations in lung tumors from p53 mutant mice exposed to cigarette smoke. Exp Lung Res, 31, 271-81. https://doi.org/10.1080/0190214059090386
  124. Yin J, Vogel U, Ma Y, et al (2007). The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer, 56, 153-60. https://doi.org/10.1016/j.lungcan.2006.12.012
  125. Yin Z, Zhou B, He Q, et al (2009). Association between polymorphisms in DNA repair genes and survival of nonsmoking female patients with lung adenocarcinoma. BMC Cancer, 9, 439. https://doi.org/10.1186/1471-2407-9-439
  126. Zanetti R, Tazi MA, Rosso S (2010). New data tells us more about cancer incidence in North Africa. Eur J Cancer, 46, 462-6. https://doi.org/10.1016/j.ejca.2009.11.012